How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 1, 2009, Pages 63-69

  Benge, Jared F ^a,b   Balsis, Steve ^c   Geraci, Lisa ^c   Massman, Paul J ^b   Doody, Rachelle S ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Alzheimer's Disease Assessment Scale; Dementia; Item response theory; Neuropsychological assessment; Psychometric assessment

Indexed keywords

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE; AMNESIA; ARTICLE; COGNITIVE DEFECT; FEMALE; HEARING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL FUNCTION; MILD COGNITIVE IMPAIRMENT; ORIENTATION; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; READING; SPEECH DISCRIMINATION; WORD RECOGNITION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; DATA INTERPRETATION, STATISTICAL; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LANGUAGE; MALE; MEMORY; MENTAL PROCESSES; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REPRODUCIBILITY OF RESULTS;

EID: 67651207189     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000230709     Document Type: Article

References (21)

1. Rosen WG, Mohs, RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
2. Rockwood K, Fay S, Gorman M, Carver D, Graham J: The clinical meaningfulness of ADAS-cog changes in Alzheimer's disease patients treated with donepezil in an openlabel trial. BMC Neurol 2007;7:26. (Pubitemid 47617930)
3. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593.
4. Hackinski V: Shifts in thinking about dementia. JAMA 2008;300:2172-2173.
5. Hambleton RK, Swaminathan H, Rogers HJ: Fundamentals of Item Response Theory. Newbury Park, Sage Publications, 1991.
6. Wouters H, van Gool W, Schmand B, Lindeboom R: Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22: 236-244.
7. Doody RS, Pavlik V, Massman P, Kenan M, Yeh S, Powell S, Cooke N, Dyer C, Demirovic J, Waring S, Chan W: Changing patient characteristics and survival experience in an Alzheimer's disease center patient cohort. Dement Geriatr Cogn Disord 2005;20:198-208. (Pubitemid 41191638)
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
9. Petersen RC, Doody R, Kurz A, et al: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992. (Pubitemid 33143977)
10. Jelic V, Kivipelto M, Winblad B: Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006;77:429-438.
11. Thissen D: Multilog User's Guide, Version 6.3. Scientific Software, 1991.
12. Samejima F: Estimation of latent ability using a response pattern of graded scores. Psychometrika Monographs 1969, No.17.
13. SPSS for Windows, Release 13.0. SPSS Inc., 2004.
14. Kim YS, Nibbelink DW, Overall JE: Factor structure and reliability of the Alzheimer's Disease Assessment Scale in a multicenter trial with linopirdine. J Geriatr Psychiatry Neurol 1994;7:74-83.
15. Kline RB: Principles and practice of structural equation modeling. New York, The Guilford Press, 2004.
16. Muthén LK, Muthén BO: MPLUS user's guide (ed 5). Los Angeles, Muthén & Muthén, 2007.
17. Tucker LR, Lewis C: A reliability coefficient for maximum likelihood factor analysis. Psychometrika 1973;38:1-10.
18. Bentler PM: Comparative fit indexes in structural models. Psychol Bull 1990;107: 238-246.
19. Harrison JC, Minassian SL, Jenkins L, et al: A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007;64:1323-1329. (Pubitemid 47403089)
20. Petersen RC: Mild underlying cognitive dys-function as a diagnostic entity. J Intern Med 2004;256:183-194.
21. Doody RS, Ferris SH, Salloway S, et al: Donepezil treatment of patients with MCI: a 48-week randomized placebo-controlled trial. Neurology 2009;72:1555-1561.